IRC
SPRO icon

Investors Research Corp’s Spero Therapeutics SPRO Stock Holding History

Investors Research Corp’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-50
Closed -$73 – 1107
2023
Q2 		$73 Hold
50
– – ﹤0.01% 1072
2023
Q1 		$73 Hold
50
– – ﹤0.01% 1105
2022
Q4 		$87 Hold
50
– – ﹤0.01% 1115
2022
Q3 		$0 Hold
50
– – ﹤0.01% 1134
2022
Q2 		$0 Hold
50
– – ﹤0.01% 1146
2022
Q1 		$0 Hold
50
– – ﹤0.01% 1088
2021
Q4 		$1K Hold
50
– – ﹤0.01% 958
2021
Q3 		$1K Hold
50
– – ﹤0.01% 967
2021
Q2 		$1K Sell
50
-10
-17% -$140 ﹤0.01% 952
2021
Q1 		$1K Sell
60
-15
-20% -$264 ﹤0.01% 945
2020
Q4 		$1K Buy
75
+45
+150% +$702 ﹤0.01% 1047
2020
Q3 		$0 Buy
+30
New +$355 ﹤0.01% 1129

Other funds holding SPRO

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Investors Research Corp's SPRO Position: Q3 2023 in Review

Investors Research Corp sold out of Spero Therapeutics (SPRO) in Q3 2023, closing a stake of 50 shares — an estimated $73 sold.

Investors Research Corp first reported a position in SPRO in Q3 2020 and held it in 12 quarters. The position peaked at $1K in Q4 2021. 54 funds tracked by Wall St. Rank hold SPRO as of Q3 2023.

  • Investors Research Corp reported no remaining Spero Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Investors Research Corp sold 50 Spero Therapeutics shares in Q3 2023, an estimated $73.
  • Investors Research Corp first reported a position in Spero Therapeutics in Q3 2020 and held it in 12 quarters.
  • Investors Research Corp's Spero Therapeutics position peaked at $1K in Q4 2021.
  • 54 funds tracked by Wall St. Rank held Spero Therapeutics as of Q3 2023.

Based on Investors Research Corp's 13F filing for Q3 2023, filed 1 Nov 2023.